Unlock the Power of IGF-1 LR3: Revolutionizing Muscle Growth and Metabolic Health
A 5-minute training-style overview, aimed at physicians, of IGF-1 LR3 covering its claimed uses, dosing, monitoring, side effects and one case example.
With Dr. Adam Sewell (MD)
Key moments
Tap a moment to play the video from there.
- 0:00Overview of the trainingSewell introduces IGF-1 LR3 as a peptide of interest for tissue repair, muscle growth and metabolic regulation, and outlines the topics ahead.
- 0:23What IGF-1 LR3 isHe describes it as an engineered analog of IGF-1 with a much longer half-life than the natural form, citing about 20 to 30 hours versus about 20 minutes.
- 1:07Claimed therapeutic applicationsSewell lists musculoskeletal injury recovery, muscle wasting, athletic recovery and metabolic syndrome, plus off-label anti-aging and bone uses.
- 1:41How it worksHe says it binds IGF-1 receptors to drive protein synthesis, cell proliferation and glucose uptake in muscle.
- 2:14Dosing protocolsHe gives a start of 20 to 40 micrograms daily, a maintenance range of 40 to 100 micrograms, and cycles of 6 to 12 weeks with a 4-week washout.
- 2:49Monitoring and labsSewell names baseline and follow-up tests, including IGF-1 every 4 weeks, glucose measures, and liver and kidney function.
- 3:24Side effects he describesHe separates mild effects such as injection-site reactions and water retention from hypoglycemia and, rarely, excessive tissue growth.
- 4:03Case study of an athleteHe recounts a 35-year-old with a hamstring tear who, he says, improved over eight weeks alongside physical therapy.
- 4:30Best practices for cliniciansSewell advises starting low, watching glucose in pre-diabetic patients, pairing use with rehabilitation, and educating patients.
- 4:57Research he citesHe points to two studies he says showed faster tissue repair and better muscle strength in muscle wasting disorders.
What the video says
This short video is presented as a training for physicians. The narrator, credited as Dr. Adam Sewell, walks through IGF-1 LR3, a modified version of IGF-1. He says it was engineered for greater stability and activity, and he contrasts a half-life of about 20 minutes for natural IGF-1 with roughly 20 to 30 hours for the LR3 variant. He also says the modification swaps one amino acid, which he links to higher receptor affinity and resistance to degradation.
Sewell lists what he describes as primary indications: recovery from tendon, ligament and muscle injuries, muscle wasting linked to chronic illness, recovery in athletes, and metabolic syndrome management. He adds what he calls off-label uses, including anti-aging protocols and bone support in osteoporosis. On mechanism, he says the peptide binds IGF-1 receptors and stimulates protein synthesis, cell proliferation and glucose uptake in muscle cells.
The dosing section is the most detailed part. Sewell describes a starting range of 20 to 40 micrograms per day by subcutaneous or intramuscular injection for 4 to 6 weeks, then 40 to 100 micrograms per day depending on goals. He says cycles usually run 6 to 12 weeks followed by a 4-week washout to avoid receptor downregulation. He recommends baseline and ongoing labs, including IGF-1, fasting glucose, HbA1c, lipids, a metabolic panel, and liver and kidney tests.
On safety, he calls it generally well tolerated and names injection-site swelling, water retention, hypoglycemia and joint pain, with excessive tissue growth and serious hypoglycemic episodes as rarer severe effects. He then describes a 35-year-old athlete with a hamstring tear who, he says, reported improvement within 4 weeks and showed accelerated tissue regeneration on MRI by week eight. He closes with best practices and two studies he says support the approach. The video is a one-speaker presentation with no on-screen data shown in the transcript.
On each compound
IGF-1 LR30:23
Sewell presents IGF-1 LR3 as a modified IGF-1 analog with a half-life he puts at 20 to 30 hours. He describes dosing, monitoring, side effects and a case example, and presents it as an option for clinicians.
See how your DNA reads IGF-1 LR3What this video doesn’t settle
- The only outcome shown is a single athlete's case, told by the presenter, with no control group and no data on screen.
- The two studies are named only loosely, and the transcript does not say whether they tested IGF-1 LR3 itself or IGF-1 more generally.
- The dosing ranges and cycle lengths are given without a cited source, and the video does not say whether any regulator has approved IGF-1 LR3 for the uses listed.
Questions this video answers
What dose of IGF-1 LR3 does Dr. Sewell describe?
Sewell describes starting at 20 to 40 micrograms per day by subcutaneous or intramuscular injection for 4 to 6 weeks. He then describes a maintenance range of 40 to 100 micrograms per day depending on goals. These are his stated protocols, not advice.
How long is an IGF-1 LR3 cycle according to this video?
Sewell says treatment cycles typically last 6 to 12 weeks, followed by a 4-week washout. He says the washout is meant to prevent receptor downregulation.
What side effects of IGF-1 LR3 does the video mention?
Sewell names mild injection-site swelling or redness and temporary water retention as common. He lists hypoglycemia and joint pain as moderate, and excessive tissue growth or hypoglycemic episodes needing medical care as rare but severe.
What labs does Sewell say to monitor with IGF-1 LR3?
He lists baseline IGF-1, fasting glucose, HbA1c, a lipid profile and a comprehensive metabolic panel. During treatment he mentions IGF-1 every 4 weeks, glucose tolerance testing, and liver and kidney tests.
Why does IGF-1 LR3 last longer than natural IGF-1, according to the video?
Sewell says the LR3 variant replaces one amino acid, which he links to higher receptor affinity and resistance to degradation. He contrasts its half-life of about 20 to 30 hours with about 20 minutes for natural IGF-1.
Video by Dr. Adam Sewell, M.D. | Medical Entrepreneur on YouTube, embedded as published. The summary is written by PeptidesDNA from the video; every claim in it is the speaker’s. Not affiliated with or endorsed by the creator. Not medical advice.
